Benjamin E. Rich

1.4k total citations
29 papers, 757 citations indexed

About

Benjamin E. Rich is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Benjamin E. Rich has authored 29 papers receiving a total of 757 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Immunology, 9 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in Benjamin E. Rich's work include Monoclonal and Polyclonal Antibodies Research (5 papers), T-cell and B-cell Immunology (5 papers) and Immune Cell Function and Interaction (4 papers). Benjamin E. Rich is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (5 papers), T-cell and B-cell Immunology (5 papers) and Immune Cell Function and Interaction (4 papers). Benjamin E. Rich collaborates with scholars based in United States, Denmark and Japan. Benjamin E. Rich's co-authors include Thomas S. Kupper, Joan A. Steitz, Önder Alpdoğan, Cornelius Schmaltz, Stephanie J. Muriglan, Jimmy A. Rotolo, Jens A. Halm, Miguel‐Angel Perales, Marcel R.M. van den Brink and Barry J. Kappel and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

Benjamin E. Rich

28 papers receiving 740 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Benjamin E. Rich United States	15	390	238	151	120	101	29	757
AH Dalloul France	14	533 1.4×	238 1.0×	145 1.0×	58 0.5×	86 0.9×	24	917
Yoshiko Matsumoto Japan	16	231 0.6×	382 1.6×	194 1.3×	166 1.4×	21 0.2×	39	897
Markus Möbs Germany	19	240 0.6×	237 1.0×	303 2.0×	40 0.3×	239 2.4×	42	802
Ella Kaganovsky Israel	13	133 0.3×	206 0.9×	127 0.8×	47 0.4×	79 0.8×	19	714
Erica Ballabio United Kingdom	19	333 0.9×	630 2.6×	271 1.8×	229 1.9×	254 2.5×	27	1.3k
Gabrıela Gualco Brazil	17	237 0.6×	168 0.7×	360 2.4×	77 0.6×	86 0.9×	36	956
Bijia Deng United States	12	534 1.4×	187 0.8×	227 1.5×	205 1.7×	25 0.2×	19	915
J.‐P. Magaud France	12	180 0.5×	252 1.1×	213 1.4×	142 1.2×	71 0.7×	24	845
A Rosolen Italy	19	252 0.6×	366 1.5×	263 1.7×	73 0.6×	37 0.4×	45	956
Ahjoku Amadi‐Obi United States	6	589 1.5×	156 0.7×	163 1.1×	73 0.6×	59 0.6×	6	991

Countries citing papers authored by Benjamin E. Rich

Since Specialization

Citations

This map shows the geographic impact of Benjamin E. Rich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benjamin E. Rich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benjamin E. Rich more than expected).

Fields of papers citing papers by Benjamin E. Rich

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Benjamin E. Rich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benjamin E. Rich. The network helps show where Benjamin E. Rich may publish in the future.

Co-authorship network of co-authors of Benjamin E. Rich

This figure shows the co-authorship network connecting the top 25 collaborators of Benjamin E. Rich. A scholar is included among the top collaborators of Benjamin E. Rich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Benjamin E. Rich. Benjamin E. Rich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fagiolini, Andrea, Yanlin Wang, Miquel Bioque, et al.. (2025). A review of clinical applications of pharmacokinetic simulations for a 2-month long-acting injectable formulation of aripiprazole. Current Medical Research and Opinion. 41(2). 317–327.

Wang, Xiaofeng, et al.. (2024). Exposure–Response Modeling in Adults and Adolescents With Schizophrenia to Support the Extrapolation of Brexpiprazole Efficacy to Adolescents. The Journal of Clinical Pharmacology. 64(10). 1236–1245. 2 indexed citations

Wang, Yanlin, et al.. (2024). Population Pharmacokinetics and Dosing Simulations for Aripiprazole 2‐Month Ready‐to‐Use Long‐Acting Injectable in Adult Patients With Schizophrenia or Bipolar I Disorder. Clinical Pharmacology in Drug Development. 13(6). 631–643. 4 indexed citations

Hanley, Michael J., Paul M. Diderichsen, Benjamin E. Rich, et al.. (2023). Response‐Based Dosing for Ponatinib: Model‐Based Analyses of the Dose‐Ranging OPTIC Study. Clinical Pharmacology & Therapeutics. 114(2). 413–422. 6 indexed citations

Sen, Adrish, Salmaan Khan, Ian A. MacNeil, et al.. (2023). Therapeutic effect of gedatolisib, a pan-PI3K/mTOR inhibitor, on prostate cancer models with PI3K or PTEN mutational status.. Journal of Clinical Oncology. 41(6_suppl). 149–149. 2 indexed citations

Li, Chao, et al.. (2022). Population pharmacokinetics and exposure–response of trilaciclib in extensive‐stage small cell lung cancer and triple‐negative breast cancer. British Journal of Clinical Pharmacology. 89(3). 1067–1079. 3 indexed citations

MacNeil, Ian A., David J. Burns, Benjamin E. Rich, et al.. (2020). New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified. Journal of Cancer Research and Clinical Oncology. 146(3). 605–619. 5 indexed citations

Gupta, Neeraj, Xiaohui Wang, Elliot Offman, et al.. (2020). Brigatinib Dose Rationale in Anaplastic Lymphoma Kinase–Positive Non‐Small Cell Lung Cancer: Exposure–Response Analyses of Pivotal ALTA Study. CPT Pharmacometrics & Systems Pharmacology. 9(12). 718–730. 14 indexed citations

Aires, Daniel, Masaru Yoshida, Stephen K. Richardson, et al.. (2018). T-cell trafficking plays an essential role in tumor immunity. Laboratory Investigation. 99(1). 85–92. 10 indexed citations

10.

Burns, David J., Benjamin E. Rich, Ian A. MacNeil, et al.. (2017). Development of a test that measures real-time HER2 signaling function in live breast cancer cell lines and primary cells. BMC Cancer. 17(1). 199–199. 14 indexed citations

11.

Burns, David J., Benjamin E. Rich, Ian A. MacNeil, et al.. (2016). A functional signal profiling test for identifying a subset of HER2-negative breast cancers with abnormally amplified HER2 signaling activity. Oncotarget. 7(48). 78577–78590. 3 indexed citations

12.

Stuckey, Daniel W., et al.. (2014). Engineering Toxin-Resistant Therapeutic Stem Cells to Treat Brain Tumors. Stem Cells. 33(2). 589–600. 26 indexed citations

13.

Kieran, Mark W., Charles W.M. Roberts, Susan Chi, et al.. (2012). Absence of oncogenic canonical pathway mutations in aggressive pediatric rhabdoid tumors. Pediatric Blood & Cancer. 59(7). 1155–1157. 58 indexed citations

14.

Rich, Benjamin E., Natalie Vena, Justin M. Craig, et al.. (2011). Detection of KIAA1549-BRAF Fusion Transcripts in Formalin-Fixed Paraffin-Embedded Pediatric Low-Grade Gliomas. Journal of Molecular Diagnostics. 13(6). 669–677. 64 indexed citations

15.

Li, Rongying, Antoni Paul, Kerry W.S. Ko, et al.. (2011). Interleukin-7 induces recruitment of monocytes/macrophages to endothelium. European Heart Journal. 33(24). 3114–3123. 48 indexed citations

16.

Bradner, James E., Edward F. Greenberg, Vishal Patel, et al.. (2007). A Soft-Drug Histone Deacetylase Inhibitor for Cutaneous T-Cell Lymphoma.. Blood. 110(11). 800–800. 3 indexed citations

17.

Gu, Ling, et al.. (2005). Combinatorial approach to identification of tyrphostin inhibitors of cytokine signaling. Bioorganic & Medicinal Chemistry. 13(13). 4269–4278. 7 indexed citations

18.

Jones, David A., et al.. (2004). Identification of Autoantigens in Psoriatic Plaques Using Expression Cloning. Journal of Investigative Dermatology. 123(1). 93–100. 34 indexed citations

19.

Rich, Benjamin E.. (2003). IL-20: a new target for the treatment of inflammatory skin disease. Expert Opinion on Therapeutic Targets. 7(2). 165–174. 19 indexed citations

20.

Rich, Benjamin E. & Thomas S. Kupper. (2001). Cytokines: IL-20 — a new effector in skin inflammation. Current Biology. 11(13). R531–R534. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact